UK markets closed

NVO Jan 2023 125.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.63000.0000 (0.00%)
As of 03:49PM EDT. Market open.
Full screen
Previous close1.6300
Open1.6000
Bid0.8000
Ask2.5000
Strike125.00
Expiry date2023-01-20
Day's range1.6000 - 1.6300
Contract rangeN/A
Volume73
Open interest332
  • Zacks

    Lilly's (LLY) Diabetes Drug Gets FDA Fast Track Tag for Obesity

    Eli Lilly (LLY) receives a fast-track designation from the FDA for tirzepatide to treat obesity in adult patients. The company will begin rolling NDA submission later this year.

  • Zacks

    Will Acquisitions Help Novo Nordisk (NVO) Combat Stiff Rivalry?

    Novo Nordisk (NVO) expects new acquisitions to diversify its portfolio of marketed drugs and help combat the stiff competition in the diabetes market.

  • Globe Newswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 3 October 2022 – On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme in